藿苏养胃口服液联合SOX方案治疗晚期胃癌的临床观察  

Clinical observation of Huosu Yangwei Syrup combined with SOX chemotherapy regimen in treating advanced gastric cancer

作　　者：朱俊燃 方盛泉[1] 陈启龙 倪红梅[3] 邓玉海[1] 李富龙[1] 傅志超 周宇轩 ZHU Junran;FANG Shengquan;CHEN Qilong;NI Hongmei;DENG Yuhai;LI Fulong;FU Zhichao;ZHOU Yuxuan(Digestive Department,Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 200437,China;Institute of Interdisciplinary Integrative Medicine Research,Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China;School of Basic Medical Sciences,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China)

机构地区：[1]上海中医药大学附属岳阳中西医结合医院消化科,上海200437 [2]上海中医药大学交叉科学研究院,上海200032 [3]上海中医药大学基础医学院,上海201203

出　　处：《上海中医药杂志》2021年第4期50-54,共5页Shanghai Journal of Traditional Chinese Medicine

基　　金：上海申康医院发展中心临床培育项目(SHDC12018X30);上海中医药大学附属岳阳中西医结合医院院级基金重点资助项目(2019YYZ01)。

摘　　要：目的观察藿苏养胃口服液联合SOX方案治疗晚期胃癌的临床疗效。方法将72例晚期胃癌患者随机分为治疗组和对照组,每组36例。对照组单纯使用SOX方案化疗,治疗组在SOX化疗方案的基础上加用藿苏养胃口服液。两组均以21 d为1个疗程,共治疗2个疗程,观察临床疗效及不良反应的发生情况,比较中医证候积分、癌症患者生命质量测定量表(EORTC QLQ-C30)评分的变化情况。结果 (1)试验过程中治疗组脱落2例、对照组脱落1例,最终完成试验者69例,其中治疗组34例、对照组35例。(2)治疗组、对照组总有效率分别为64.71%、14.29%,治疗组临床疗效优于对照组。(3)治疗前后组内比较,治疗组中医证候积分减少(P<0.05),对照组中医证候积分差异无统计学意义(P>0.05);组间治疗前后中医证候积分差值比较,差异有统计学意义(P<0.05)。(4)在EORTC QLQ-C30量表评分方面,治疗组疲劳、恶心呕吐、食欲丧失领域评分的改善情况优于对照组(P<0.05)。(5)治疗组、对照组贫血发生率分别为47.06%、71.43%,恶心呕吐发生率分别为8.82%、54.29%;两组化疗后贫血及恶心呕吐发生率比较,差异有统计学意义(P<0.05)。结论与单纯采用SOX化疗方案相比,联合使用藿苏养胃口服液治疗晚期胃癌疗效满意,能更好地改善患者的临床症状,提高生存质量,降低化疗药物不良反应(贫血、恶心呕吐)发生率。Objective To observe the clinical effect of Huosu Yangwei Syrup combined with SOX chemotherapy regimen in the treatment of advanced gastric cancer(AGC). Methods A total of 72 AGC patients were randomly divided into treatment group(n=36) and control group(n=36). The control group was administered with SOX chemotherapy regimen alone, while the treatment group was administered with Huosu Yangwei Syrup besides SOX chemotherapy regimen. Both groups were treated for two courses of treatment, with 21 days as one course of treatment. The clinical efficacy and the incidence of adverse reactions were observed. The changes of TCM syndrome scores and the EORTC Core Quality of Life questionnaire(EORTC QLQ-C30) scores were compared. Results(1)During the trial, there were 2 drop-out cases in the treatment group and 1 drop-out case in the control group. A total of 69 patients finally completed the trail, including 34 cases in the treatment group and 35 cases in the control group.(2)The total effective rates of the treatment group and the control group were 64. 71% and14.29% respectively,and the clinical efficacy of the treatwent group was significantly better than that of the control group( P <0.05).(3)According to the intra-group comparison before and after treatment, the TCM syndrome scores in the treatment group decreased after treatment( P<0.05),but there was no significant difference in the TCM syndrome scores in the control group( P >0.05);According to the inter-group comparison before and after treatment,the differences in the TCM syndrome scores were statistically significant( P<0.05).(4)The improvement of fatigue,nausea,vomiting and loss of appetite in the treatment group was better than that in the control group( P<0.05) according to the EORTC QLQ-C30 scores.(5)The incidence of anemia was 47.06% in the treatment group and 71.43% in the control group,and the incidence of nausea and vomiting was 8.82% in the treatment group and 54.29% in the control group. There was statistically significant difference in the incidence o

关 键 词：胃癌 晚期 藿苏养胃口服液 替吉奥 奥沙利铂 

分 类 号：R735.2[医药卫生—肿瘤]